|
Daily Medical Update
Immunizations: Adult/Elderly (RSV, Pneumococcal, Shingles)
Thursday, February 26, 2026
|
🔬 Practice‑Changing Findings
Evidence from RCTs and meta‑analyses published in the last 12 months.
|
Vaccine (2025) - Systematic Review and Meta-Analysis of RCTs
Key Findings
- Pooled randomized evidence in older adults favored RSV vaccination over placebo for prevention of RSV lower respiratory outcomes.
- Serious adverse events were not clearly increased versus control groups, while expected local/systemic reactogenicity remained mostly short-lived.
📋 Practice Implication: Make RSV vaccine a routine seasonal recommendation for eligible adults ≥60 during preventive visits, especially with chronic heart/lung disease.
|
Lancet Infectious Diseases (2025) - Phase 3 Randomized Trial Follow-up
Key Findings
- Three-season follow-up data demonstrated sustained vaccine protection against RSV lower respiratory disease in older adults.
- Extended monitoring did not reveal a major new safety signal, supporting durability and tolerability in longitudinal use.
📋 Practice Implication: When patients ask if RSV vaccination wears off quickly, counsel that protection appears durable across subsequent seasons based on trial follow-up.
|
JACC (2025) - Prespecified Analysis of Randomized Trial
Key Findings
- A prespecified analysis reported fewer cardiovascular hospitalizations in vaccinated older adults compared with controls.
- Benefit direction was preserved in participants with baseline atherosclerotic cardiovascular disease, a high-risk primary care subgroup.
📋 Practice Implication: In high-risk ASCVD patients, frame RSV vaccination as potentially cardiopulmonary-protective rather than solely infection-preventive to improve uptake.
|
Vaccine (2026) - Randomized Clinical Trials
Key Findings
- Recent adult phase 3 trials of higher-valent pneumococcal conjugate vaccines demonstrated broad serotype-specific immune responses.
- Across trial arms, reactogenicity was mainly mild-to-moderate and serious adverse-event rates were similar between investigational and comparator vaccines.
📋 Practice Implication: Update clinic protocols to prioritize current higher-valent conjugate options for at-risk adults instead of defaulting to older lower-valent pathways.
|
BMC Infectious Diseases (2025) - Systematic Review and Meta-Analysis
Key Findings
- Meta-analytic data linked pneumococcal vaccination with lower hospitalization rates for severe respiratory illness in older adults.
- Pooled estimates favored vaccination for mortality-related outcomes, reinforcing prevention value beyond incident pneumonia counts alone.
📋 Practice Implication: Use hospitalization and mortality prevention language in counseling to improve pneumococcal vaccine acceptance among hesitant older adults.
|
Rheumatology (2025) - Randomized Trial/Extension
Key Findings
- Adults with autoimmune rheumatic disease developed sustained immune responses after adjuvanted recombinant zoster vaccination.
- Follow-up did not show major excess flare burden or severe vaccine-related complications versus expectations for this population.
📋 Practice Implication: Stop treating stable autoimmune disease as a default reason to postpone shingles vaccination; coordinate timing but complete the 2-dose RZV series.
|
J Am Pharm Assoc (2025) - Implementation Trial
Key Findings
- Team-based pharmacist outreach increased completion rates across several adult vaccines in older populations.
- Programs reduced missed opportunities compared with usual physician-only opportunistic counseling workflows.
📋 Practice Implication: Adopt standing orders and pharmacist co-management to close adult vaccine gaps faster than clinician-only visit-based reminders.
|
|
Recent evidence supports aggressive adult respiratory and zoster immunization in primary care, especially for older adults and patients with cardiopulmonary or immune-mediated disease. Across RSV, pneumococcal, and shingles studies, the most practice-relevant gains are reduced severe respiratory outcomes, durable multi-season protection, and strong immunogenicity in higher-risk groups. The biggest workflow lever is reducing missed opportunities via same-visit coadministration and team-based outreach.
|
|